121 related articles for article (PubMed ID: 38893073)
41. Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients.
Pan CW; He JY; Zhu YB; Zhao CH; Luo N; Wang P
Eur J Health Econ; 2023 Aug; 24(6):885-893. PubMed ID: 36083356
[TBL] [Abstract][Full Text] [Related]
42. Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients.
Golicki D; Niewada M; Karlińska A; Buczek J; Kobayashi A; Janssen MF; Pickard AS
Qual Life Res; 2015 Jun; 24(6):1555-63. PubMed ID: 25425288
[TBL] [Abstract][Full Text] [Related]
43. Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients.
Lloyd AJ; Kerr C; Penton J; Knerer G
Value Health; 2015 Dec; 18(8):1152-7. PubMed ID: 26686802
[TBL] [Abstract][Full Text] [Related]
44. Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30.
Krabbe PF; Peerenboom L; Langenhoff BS; Ruers TJ
Qual Life Res; 2004 Sep; 13(7):1247-53. PubMed ID: 15473503
[TBL] [Abstract][Full Text] [Related]
45. An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences.
Crott R; Versteegh M; Uyl-de-Groot C
Qual Life Res; 2013 Jun; 22(5):1045-54. PubMed ID: 22743734
[TBL] [Abstract][Full Text] [Related]
46. A longitudinal validation of the EQ-5D-5L and EQ-VAS stand-alone component utilising the Oxford Hip Score in the Australian hip arthroplasty population.
Lin DY; Cheok TS; Samson AJ; Kaambwa B; Brown B; Wilson C; Kroon HM; Jaarsma RL
J Patient Rep Outcomes; 2022 Jun; 6(1):71. PubMed ID: 35723750
[TBL] [Abstract][Full Text] [Related]
47. Patient-centered Outcomes in Breast Cancer: Description of EQ-5D-5L and EORTC-QLQ-BR23 Measurements in Real-world Data and Their Association With Survival.
Monteiro MR; Nunes NCC; Crespo J; Abrahão ABK; Buscacio G; Lerner LCC; Sermoud L; Arakelian R; Piotto G; Lemos C; Campos R; Victorino D; Andrade PM; Ferreira TAV; Pecoraro JP; Meton F; Gaui MF; Araujo LH
Clin Oncol (R Coll Radiol); 2022 Sep; 34(9):608-616. PubMed ID: 35667940
[TBL] [Abstract][Full Text] [Related]
48. A vision 'bolt-on' increases the responsiveness of EQ-5D: preliminary evidence from a study of cataract surgery.
Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N
Eur J Health Econ; 2020 Jun; 21(4):501-511. PubMed ID: 31902023
[TBL] [Abstract][Full Text] [Related]
49. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
Lamu AN; Olsen JA
Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
[TBL] [Abstract][Full Text] [Related]
50. Estimation of Health-Related Utilities for
Soare IA; Leeuwenkamp O; Longworth L
Pharmacoecon Open; 2021 Dec; 5(4):715-725. PubMed ID: 34260017
[TBL] [Abstract][Full Text] [Related]
51. Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study.
Kawata AK; Lenderking WR; Eseyin OR; Kerstein D; Huang J; Huang H; Zhang P; Lin HM
J Med Econ; 2019 Sep; 22(9):924-935. PubMed ID: 31125274
[No Abstract] [Full Text] [Related]
52. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
53. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
[TBL] [Abstract][Full Text] [Related]
54. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
Rischin D; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Braña I; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Ishak WZW; Hong RL; Mendoza RG; Jia L; Chirovsky D; Norquist J; Jin F; Burtness B
Oral Oncol; 2022 May; 128():105815. PubMed ID: 35381576
[TBL] [Abstract][Full Text] [Related]
55. Validation of EORTC QLQ-C30 and QLQ-BR23 questionnaires in the measurement of quality of life of breast cancer patients in Singapore.
Tan ML; Idris DB; Teo LW; Loh SY; Seow GC; Chia YY; Tin AS
Asia Pac J Oncol Nurs; 2014; 1(1):22-32. PubMed ID: 27981079
[TBL] [Abstract][Full Text] [Related]
56. Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review.
Ratti MM; Gandaglia G; Alleva E; Leardini L; Sisca ES; Derevianko A; Furnari F; Mazzoleni Ferracini S; Beyer K; Moss C; Pellegrino F; Sorce G; Barletta F; Scuderi S; Omar MI; MacLennan S; Williamson PR; Zong J; MacLennan SJ; Mottet N; Cornford P; Aiyegbusi OL; Van Hemelrijck M; N'Dow J; Briganti A;
Eur Urol Oncol; 2022 Apr; 5(2):153-163. PubMed ID: 34785188
[TBL] [Abstract][Full Text] [Related]
57. Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes.
Catto JWF; Downing A; Mason S; Wright P; Absolom K; Bottomley S; Hounsome L; Hussain S; Varughese M; Raw C; Kelly P; Glaser AW
Eur Urol; 2021 May; 79(5):621-632. PubMed ID: 33581875
[TBL] [Abstract][Full Text] [Related]
58. Validity and reliability of the EQ-5D for cancer patients in Korea.
Kim SH; Hwang JS; Kim TW; Hong YS; Jo MW
Support Care Cancer; 2012 Dec; 20(12):3155-60. PubMed ID: 22488293
[TBL] [Abstract][Full Text] [Related]
59. Correction: Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after.
Miret C; Orive M; Sala M; García-Gutiérrez S; Sarasqueta C; Legarreta MJ; Redondo M; Rivero A; Castells X; Quintana JM; Garin O; Ferrer M;
Qual Life Res; 2024 May; 33(5):1433-1435. PubMed ID: 38457055
[No Abstract] [Full Text] [Related]
60. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice.
Lorusso D; Colombo N; Herraez AC; Santin AD; Colomba E; Miller DS; Fujiwara K; Pignata S; Baron-Hay SE; Ray-Coquard IL; Shapira-Frommer R; Kim YM; McCormack M; Massaad R; Nguyen AM; Zhao Q; McKenzie J; Prabhu VS; Makker V
Eur J Cancer; 2023 Jun; 186():172-184. PubMed ID: 37086595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
